Does EVOLOCUMAB Cause Type iia hyperlipidaemia? 66 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 66 reports of Type iia hyperlipidaemia have been filed in association with EVOLOCUMAB (REPATHA). This represents 0.0% of all adverse event reports for EVOLOCUMAB.
66
Reports of Type iia hyperlipidaemia with EVOLOCUMAB
0.0%
of all EVOLOCUMAB reports
55
Deaths
14
Hospitalizations
How Dangerous Is Type iia hyperlipidaemia From EVOLOCUMAB?
Of the 66 reports, 55 (83.3%) resulted in death, 14 (21.2%) required hospitalization, and 1 (1.5%) were considered life-threatening.
Is Type iia hyperlipidaemia Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EVOLOCUMAB. However, 66 reports have been filed with the FAERS database.
What Other Side Effects Does EVOLOCUMAB Cause?
Device difficult to use (31,807)
Drug dose omission by device (23,957)
Wrong technique in product usage process (21,664)
Accidental exposure to product (16,160)
Injection site pain (9,988)
Product storage error (6,606)
Back pain (5,254)
Myalgia (5,061)
Drug dose omission (4,914)
Injection site bruising (4,409)
What Other Drugs Cause Type iia hyperlipidaemia?
ATORVASTATIN (67)
EZETIMIBE (67)
ROSUVASTATIN (63)
SIMVASTATIN (63)
LOMITAPIDE (59)
LOVASTATIN (56)
PROBUCOL (56)
IMPLITAPIDE (49)
CAFFEINE\PROCAINE (10)
TOCILIZUMAB (8)
Which EVOLOCUMAB Alternatives Have Lower Type iia hyperlipidaemia Risk?
EVOLOCUMAB vs EXELON
EVOLOCUMAB vs EXEMESTANE
EVOLOCUMAB vs EXENATIDE
EVOLOCUMAB vs EXFORGE
EVOLOCUMAB vs EXJADE